

35 **Abstract**

36 We undertook a point-of-care test (POCT) for hepatitis B core-related antigen (HBcrAg) on
37 adults living with HBV in Kilifi, Kenya. A positive test identified all with hepatitis B viral load
38 >200,000 IU/ml, who were HBeAg positive, and correlated with higher ALT ($p = 0.03$), raised
39 APRI ($p < 0.001$) and elastography scores ($p = 0.03$).

40

41 **Introduction**

42 The 2024 Global Hepatitis Report highlights significant morbidity and mortality due to chronic
43 hepatitis B virus infection (CHB), with the number of people dying from CHB rising from 820,000
44 in 2019 to 1.1 million in 2022, disproportionately affecting populations in the WHO African
45 Region (WHO-AFRO) (1).

46

47 One of the most significant barriers to HBV elimination in this region is that only 0.2% of people
48 living with HBV (PLWHB) are on treatment (1) and tests for risk-stratification are often
49 inaccessible and unaffordable. New 2024 WHO HBV management guidelines simplify
50 assessment, but still recommend alanine aminotransferase (ALT) measurement or aspartate
51 transaminase (AST) to platelet ratio index (APRI) calculation (2) along with HBV viral load (VL)
52 measurement to determine long-term treatment eligibility. HBV VL measurement and/or
53 hepatitis B e antigen (HBeAg) assessment are also recommended to determine eligibility for
54 peri-partum antiviral prophylaxis (3).

55

56 Point-of-care tests (POCTs) offer an attractive alternative to these laboratory assays, allowing
57 real-time feedback, potentially improving retention in clinical care and viral suppression rates
58 (4). Currently, liver stiffness measurement using elastography is the only validated POCT for
59 assessing liver health for PLWHB; however, the hardware is prohibitively expensive. Current
60 POCTs for HBeAg have poor sensitivity (5,6), and HBV VL measurements require a laboratory
61 platform like Gene Xpert (Cepheid Inc., CA, USA).

62

63 Hepatitis B core-related antigen (HBcrAg) correlates with peripheral HBV DNA and HBeAg
64 status in untreated individuals (7) and could be an alternative to HBV VL quantification in low
65 resource settings (8). HBcrAg has previously only been available as a chemiluminescent assay
66 (CLEIA). A new HBcrAg POCT performed well in The Gambia as a surrogate for HBV VL, but
67 has not yet been assessed elsewhere in the general adult population with CHB in WHO-AFRO
68 countries, and performance has not been evaluated against ALT or liver fibrosis. We set out to

69 evaluate the HBcrAg-POCT in PLWHB in Kilifi, Kenya, considering (i) the ease of testing, (ii) its
70 relationship with ALT, HBeAg status, HBV VL and elastography, and (iii) its contribution to
71 determining treatment eligibility.

72

73 **Methods**

74 PLWHB were recruited through the STRIKE-HBV study at KEMRI-Wellcome Trust Research
75 Programme (KWTRP), which identified 102 non-pregnant adults from Kilifi County, Kenya as
76 previously described (10). Positive HBsAg POCT results were confirmed with an enzyme linked
77 immunoassay (ELISA) (Murex HBsAg 3, Diasorin). The cohort was 60% female, median age 37
78 years (IQR 28-49 years), and two people were also living with HIV infection.

79

80 Liver elastography was undertaken at recruitment (Echosens, Paris, France), and blood
81 samples were drawn and transported to the research laboratory within 2-3 hours of collection,
82 spun to separate serum, and frozen in aliquots at -80°C. Routine laboratory markers were
83 measured in a validated diagnostic clinical laboratory at KWTRP, including ALT, AST (Ilab
84 Aries) and platelets (AcT 5diff CP, Beckman Coulter) for APRI score calculation.

85

86 HBeAg was tested at the KWTRP research laboratory using CLEIA (Ig Biotechnology, CA, US),
87 HBV VL was tested at Oxford University Hospitals, UK using the Abbott Alinity (Illinois, USA).
88 The HBcrAg-POCT (ESPLINE™ (RUO), Fujirebio, Japan) was shipped from Kumamoto
89 University, Japan, stored at room temperature and undertaken retrospectively on 50µls
90 defrosted serum in the KWTRP laboratories as per manufacturer's instructions (9); no specific
91 training was required. The testing was performed in three batches by clinical and laboratory
92 staff, blinded to patient details including HBV VL and HBeAg status. Positive and negative
93 controls were provided and undertaken once prior to each batch testing.

94

95 Liver health thresholds and treatment eligibility criteria were taken from the 2024 WHO HBV
96 guidelines (2) as follows: elastography score >7.0kPa = significant fibrosis, >12.5kPa =
97 cirrhosis; APRI >0.5 = significant fibrosis, >1.0 = cirrhosis. Those with i) elastography score
98 >7kPa; OR ii) APRI score >0.5; OR iii) HBV DNA >2000 IU/ml AND ALT > upper limit of normal
99 (ULN, 19 IU/L for women, 30 IU/L for men), were defined as treatment eligible. In the untreated
100 population, we first investigated whether ALT alone could identify those who were treatment
101 eligible, then evaluated the contribution of the HBcrAg POCT.

102

103 Statistical analysis was done using R version 4.2.0. The study was approved by the Scientific
104 Ethics Review Unit (SERU 4565) and Oxford Tropical Network Ethics Committee (OxTREC 23-
105 22).

106

107 **Results**

108 HBcrAg-POCT was positive in 14/102 PLWHB (14%) – with a positivity rate of 4/61 (7%) in
109 women and 10/41 (24%) in men (($p=0.01$). Those with a positive-POCT were younger (median
110 age 28 years compared to 38 years with a negative-POCT, $p=0.03$). There was no difference in
111 current antiviral treatment status between those testing POCT-positive or negative (table 1).
112 Laboratory personnel reported the POCT twas easy to perform. The test turnaround time was
113 approximately 40 minutes.

114

115 ***Analysis in the untreated population***

116 75 PLWHB were untreated on cohort entry (42 female, 33 male). Median age was 40 years
117 (IQR 27 - 49) among whom 11/75 (15%) had a positive HBcrAg POCT. This group had a
118 significantly higher median HBV DNA level than those with a negative POCT ($6.05 \log_{10}$ IU/ml vs
119 $2.7 \log_{10}$ IU/ml, respectively; $p < 0.001$, table 1). To identify those testing HBV DNA $>200,000$
120 IU/ml, HBcrAg-POCT had a sensitivity of 100% (7/7) (supp figure 1) and a specificity of 94%
121 (64/68). All those who had HBV DNA $>200,000$ IU/ml also carried HBeAg (table 1).

122

123 A positive HBcrAg-POCT was significantly associated with a higher median ALT than a negative
124 test (58 IU/L vs 26 IU/L, $p=0.006$, table 1). Individuals with a positive HBcrAg-POCT were more
125 likely to meet elastography criteria for significant fibrosis or cirrhosis than those with a negative
126 POCT (supp figure 1, 3/11, (27%) vs 6/64 (9%) with a negative test, $p=0.03$), but there was no
127 significant difference in median elastography score between those with a positive and negative
128 HBcrAg-POCT. Those with a positive HBcrAg-POCT had higher median APRI scores (0.57 vs
129 0.29, $p = 0.003$), and were more likely to meet APRI criteria for significant fibrosis or cirrhosis
130 (supp figure 1, 8/11(73%) vs 6/63, (10%), respectively; $p < 0.001$ (table 1).

131

132 In this currently untreated group, 27/75 (36%) people met treatment criteria as defined. Among
133 these, 23/27 (85%) would have been identified based on ALT criteria alone, whereas a positive
134 HBcrAg-POCT alone would have only identified 9/27 (33%) (supp table 1). Of the four people
135 not identified by ALT, one had a positive HBcrAg-POCT, but the other three did not, so would
136 have been missed by both tests. Therefore the addition of HBcrAg POCT to ALT identified one

137 extra treatment eligible person compared to using ALT alone (supp. figure 2). This individual
138 also had a high HBV VL of 6.1 log₁₀IU/ml and fibroscan score of 10.1kPa, suggesting some
139 existing liver fibrosis and a risk of progressive chronic liver disease.

140

141 **Discussion**

142 This is the first report directly comparing the HBcrAg-POCT with ALT, markers of liver fibrosis,
143 and HBeAg status. Here, a positive HBcrAg-POCT was strongly associated with liver
144 inflammation by ALT, and fibrosis/cirrhosis by both Fibroscan and APRI scores. However, the
145 HBcrAg-POCT alone identified fewer people meeting treatment eligibility scores by APRI or
146 Fibroscan than ALT alone. Addition of the POCT to ALT did identify one extra person as
147 treatment eligible who was at high risk of complications, however further assessment is needed
148 to see if this benefit translates to larger populations.

149

150 In this cohort, a positive HBcrAg-POCT was 100% sensitive at identifying HBeAg positivity,
151 performing much better than currently available HBeAg-POCTs which have sensitivities ranging
152 from 30-62% (5,6). A positive HBcrAg-POCT was 100% sensitive at identifying those with HBV
153 VL >200,000 IU/ml, which is a higher sensitivity than what was found when this POCT was
154 trialled in the Gambia. This POCT is therefore of potential clinical utility to identify individuals
155 eligible for perinatal antiviral prophylaxis. This is the first time this has been shown in East
156 Africa, where circulating HBV genotypes differ from those in West Africa.

157

158 This HBcrAg-POCT is quick and could be undertaken without specific training. It is relatively low
159 production cost (<\$5 per test), compared to HBV VL which varies in price across WHO AFRO
160 up to \$62/test (1), and HBeAg up to \$40/test for the laboratory ELISA (11,12) assuming these
161 tests are actually available. ALT is relatively low cost (<\$10) and available in much of WHO-
162 AFRO, so continues to be a good method of liver health assessment in the absence of other
163 tests. Further implementation research is needed to determine whether inclusion of the
164 HBcrAg-POCT alongside ALT could enhance linkage to care and improve decentralisation of
165 clinical assessment, and how its impact and cost-effectiveness varies by setting.

166

167 The number of PLWHB included in this study was small, from a specific geographical region
168 and did not include children/adolescents or pregnant women. We did not have access to a
169 HBeAg POCT or gold standard method of assessing liver disease such as cross-sectional
170 imaging or liver biopsy.

171 **Conclusion**

172 HBcrAg-POCT correlates strongly with several liver disease markers in PLWHB. However, it
173 does not perform better than ALT at identifying those with abnormal elastography or APRI
174 scores, so should be used as an adjunct rather than stand-alone. It could provide a low-cost
175 alternative to some otherwise unavailable, unaffordable diagnostics.

176

177 **Funding**

178 PCM receives core funding from the Francis Crick Institute (Ref: CC2223) and from University
179 College London Hospitals NIHR Biomedical Research Centre (BRC). LD is funded by a
180 Wellcome Doctoral Training Fellowship (grant number 225485/Z/22/Z) and by the Oxford
181 Hospitals Charity Grant ref 1351. The study was partly funded by the JSPS KAKENHI
182 (JP21K10416) and the Pasteur International Joint Research Unit. The funders had no role in
183 study design, data collection and analysis, decision to publish, or preparation of the manuscript.

184

185 **Acknowledgements**

186 We thank Fujirebio Inc. for providing test reagents and to all the staff at the Comprehensive
187 Care Clinic, outpatients department and Maternal Child Health Clinics at Kilifi County Referral
188 Hospital for assisting in study recruitment.

189

190 **Author Contributions**

191 LOD, DO, YS and PCM conceptualised the manuscript

192 LOD, PCM, NA, MIA, AOE and GG designed the study

193 LOD, OC, MZ, BS and NA enrolled patients and collected study data and serum samples

194 DO and LOD undertook the point of care tests in the KWTRP laboratories

195 YS and YT provided the point of care test kits and gave technical advice and oversight on the
196 use of the point of care tests.

197 LOD undertook data analysis with advice provided by AOE, YS, GG and PCM.

198 All authors reviewed and commented on the manuscript prior to submission.

199

200 **Conflicts of Interest**

201 YS has received a research grant and honoraria for lectures from Gilead Sciences and research
202 materials from Abbott Laboratories and Fujirebio Inc. PCM has previously received funding
203 support for her group from GSK (outside the scope of this paper). YT has received scholarship
204 donations from AbbVie GK and OTSUKA Pharmaceutical Co. and research funding from

205 AbbVie GK, Fujirebio Inc, Sysmex Corp, GSK, Gilead Sciences and Janssen Pharmaceuticals.
206 YT has also received lecture fees from AbbVie GK, Gilead Sciences, Chugai Pharmaceuticals,
207 ASKA Pharmaceutical Holdings, OTSUKA Pharmaceutical Co., Takeda Pharmaceutical Co,
208 GSK, AstraZeneca, Eisai and HU Frontier.

209

210 **Data Availability**

211 For the purpose of Open Access, the author has applied a CC-BY public copyright license to
212 any author accepted manuscript version arising from this submission. Data supporting the
213 findings of this study will be publicly available on the acceptance of the manuscript for
214 publication. This manuscript was written with the permission of Director KEMRI CGMRC.

215 **Table 1:** Characteristics of 102 adults with chronic HBV infection in Kilifi, Kenya, assessed with a point of
 216 care test (POCT) for Hepatitis B core-related antigen (HBcrAg).
 217

| Characteristic (all participants) | N=102 | Negative HBcrAg POCT n = 88 ¹ | Positive HBcrAg POCT n = 14 ¹ | p-value ² |
|---|-------|---|---|----------------------|
| Sex | 102 | | | 0.010 |
| Female | 61 | 57 (93%) | 4 (7%) | |
| Male | 41 | 31 (76%) | 10 (24%) | |
| Age in years, median (IQR) | 102 | 38 (30, 49) | 28 (27, 39) | 0.03 |
| Unknown | 1 | | | |
| On Antiviral Therapy | 102 | | | 0.8 |
| Yes | 27 | 24 (89%) | 3 (11%) | |
| No | 75 | 64 (85%) | 11 (15%) | |
| Characteristic (untreated group) | N=75 | Negative HBcrAg POCT n = 64 ¹ | Positive HBcrAg POCT n = 11 ¹ | p-value ² |
| HBV DNA (log₁₀ IU/ml), median (IQR) | 74 | 2.68 (1.56, 3.45) | 6.05 (3.19, 7.03) | <0.001 |
| HBV DNA Group (log₁₀ IU/ml) | 75 | | | <0.001 |
| <20 | 13 | 12 (92%) | 1 (8%) | |
| 20 - 2000 | 36 | 34 (94%) | 2 (6%) | |
| 2000 - 20,000 | 15 | 14 (93%) | 1 (7%) | |
| 20,000 - 200,000 | 3 | 3 (100%) | 0 (0%) | |
| >200,000 | 7 | 0 (0%) | 7 (100%) | |
| Unknown | 1 | 1 | 0 | |
| ALT U/L, median (IQR) | 75 | 26 (19, 35) | 58 (31, 67) | 0.006 |
| ALT >ULN | 75 | | | 0.7 |
| Yes | 48 | 40 (83%) | 8 (17%) | |
| No | 27 | 24 (89%) | 3 (11%) | |
| Elastography score (kPa), median (IQR) | 66 | 4.25 (3.50, 5.55) | 6.65 (3.50, 8.98) | 0.2 |
| Unknown | 9 | 6 | 3 | |
| Liver Health Fibroscan | 75 | | | 0.03 |

| | | | | |
|--|----|-------------------|-------------------|------------------|
| Normal (≤ 7 kPa) | 57 | 52 (91%) | 5 (9%) | |
| Significant fibrosis ($>7 - \leq 12.5$ kPa) | 8 | 6 (75%) | 2 (25%) | |
| Cirrhosis (>12.5 kPa) | 1 | 0 (0%) | 1 (100%) | |
| Unknown | 9 | 6 | 3 | |
| APRI Score, median (IQR) | 74 | 0.29 (0.22, 0.39) | 0.57 (0.34, 0.86) | 0.003 |
| Unknown | 1 | 1 | 0 | |
| Liver health APRI | 75 | | | <0.001 |
| Normal (<0.5) | 60 | 57 (95%) | 3 (5%) | |
| Significant Fibrosis (0.5 - 1) | 11 | 5 (45%) | 6 (55%) | |
| Cirrhosis (>1) | 3 | 1 (33%) | 2 (67%) | |
| Unknown | 1 | 1 | 0 | |
| HBeAg | 75 | | | <0.001 |
| Positive | 7 | 0 (0%) | 7 (100%) | |
| Negative | 68 | 64 (94%) | 4 (6%) | |

¹n (%); Median (IQR), ²Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test

218 IQR - interquartile range, ALT - alanine aminotransferase, ULN - upper limit of normal, kPa - kilopascals,

219 APRI - AST to platelet ratio index, HBeAg - hepatitis B 'e' antigen.

220

221

| Meeting treatment criteria | Identified by ALT alone | Identified by HBcrAg-POCT alone | Identified by ALT AND HBcrAg-POCT together |
|----------------------------|-------------------------|---------------------------------|--|
| 27/75 (36%) | 23/27 (85%) | 9/27 (33%) | 24/27 (89%) |

222

223 **Supplementary Table 1:** The number of people living with hepatitis B virus infection in Kilifi, Kenya

224 meeting treatment criteria (defined as Fibroscan score >7 kPa, or APRI score >0.5 , or the combination of

225 raised ALT AND HBV DNA >2000 IU/ml) compared with how many of these people would have been


226 identified using ALT alone, HBcrAg-POCT alone or by both tests. APRI: Aspartate transaminase-to-

227 platelet ratio index, ALT: Alanine aminotransferase, HBcrAg-POCT: Hepatitis B core-related antigen

228 point-of-care test. Treatment criteria: Fibroscan score >7 kPa or APRI score >0.5 .

229

230



231

232 **Supplementary figure 1:** Relationship between clinical characteristics and results of HBcrAg point-of-
233 care test in adults living with hepatitis B virus infection (HBV) in Kilifi, Kenya: A - HBeAg status, B - HBV
234 VL level, C - liver health based on APRI scores, D - Liver stiffness by elastography scores. Each
235 characteristic is split by hepatitis B core-related antigen (HBcrAg) POCT test result. Light grey is those
236 testing HBcrAg POCT negative, dark grey is those testing HBcrAg POCT positive. HBeAg: hepatitis B 'e'
237 antigen, VL: viral load, APRI: Aspartate transaminase to platelet ratio index. APRI scores: Normal <0.5,
238 Significant fibrosis 0.5 - 1, Cirrhosis >1. Elastography scores: Normal <7 kPa, Significant fibrosis 7-12.5
239 kPa, Cirrhosis >12.5 kPa.

- 258 4. Drain PK, Dorward J, Violette LR, Quame-Amaglo J, Thomas KK, Samsunder N, et al.
259 Point-of-care HIV viral load testing combined with task shifting to improve treatment
260 outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled
261 trial. *Lancet HIV*. 2020 Apr 1;7(4):e229–37.
- 262 5. Seck A, Ndiaye F, Maylin S, Ndiaye B, Simon F, Funk AL, et al. Poor sensitivity of
263 commercial rapid diagnostic tests for hepatitis B e antigen in Senegal, west Africa. *Am J*
264 *Trop Med Hyg*. 2018 Aug;99(2):428–34.
- 265 6. Leathers JS, Pisano MB, Re V, Van Oord G, Sultan A, Boonstra A, et al. Evaluation of
266 rapid diagnostic tests for assessment of Hepatitis B in resource-limited settings. *Ann Glob*
267 *Health [Internet]*. 2019 Jul 4 [cited 2024 Oct 16];85(1). Available from:
268 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634443/>
- 269 7. Mak LY, Wong DKH, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B
270 core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
271 *Aliment Pharmacol Ther*. 2018 Jan 1;47(1):43–54.
- 272 8. Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Mohammad S, et al. Clinical
273 Infectious Diseases Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus
274 DNA to Assess Treatment Eligibility in Africa. *Clinical Infectious Diseases*®.
275 2020;70(7):1442–52.
- 276 9. Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y, et al. Rapid point-of-
277 care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited
278 settings. *Clin Gastroenterol Hepatol [Internet]*. 2022 Jun;0(0). Available from:
279 <http://www.cghjournal.org/article/S1542356522005547/fulltext>
- 280 10. Downs LO, Chirro O, Zaharani M, Safari B, Okanda D, Githinji G, et al. STRIKE-HBV:
281 establishing an HBV screening programme in Kilifi, Kenya-challenges, successes and
282 lessons learnt. *Sex Transm Infect [Internet]*. 2024 May 24; Available from:
283 <http://dx.doi.org/10.1136/sextrans-2024-056163>
- 284 11. Gosset A, Drabo S, Carrieri P, Tiendrebeogo ASE, Vincent JP, Tanaka Y, et al. Costs of
285 integrating hepatitis B screening and antiviral prophylaxis into routine antenatal care in
286 Burkina Faso: Treat all versus targeted strategies. *Int J Gynaecol Obstet*. 2024 Jul
287 1;166(1):44–61.
- 288 12. Nayagam S, de Villiers MJ, Shimakawa Y, Lemoine M, Thursz MR, Walsh N, et al. Impact
289 and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation
290 modelling study. *Lancet Gastroenterol Hepatol*. 2023 Jul;8(7):635–45.

291